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VALIDATION OF A 96-WELL PLATE BASED ATP ASSAY
FOR DETERMINING CHEMOSENSITIVITY OF LEUKAEMIC
BLAST CELLS
TB Davis 1, CJ Williamson 3, JM Sargent 3, F van Delft 2, V Saha 2,
SP Joel 1
1 London, United Kingdom, United Kingdom, 2 London,
United Kingdom, United Kingdom
The MTT assay  has  been used  for the in vitro  determination  of 
chemosensitivity in childhood ALL blast cells, but can be limited by the 
number of available cells. We have investigated the ViaLightTM  tTM  HS ATP assay 
(Cambrex Bioscience, Wokingham, UK), a more sensitive technique that 
uses up to 10 times fewer blast cells than the traditional MTT assay, for this
purpose.  Ficoll density separated blast cells from bone marrow or peripheral
blood from children diagnosed with ALL or AML were thawed, washed with 
RPMI 1640 with 20% FBS and resuspended in RPMI 1640 with 10% FBS, 
100IU penicillin and 100µg/ml streptomycin.  Cell count and viability were
measured using the trypan blue exclusion method and 5x105 cells/ml plated 
into 96-well plates. Cells were then exposed to cytotoxic drugs at a minimum 
of 4 concentrations in triplicate for 48 or 96 hours (depending on the drug) in 
a humidiﬁ  ed atmosphere of 5% CO2 at 370C. After drug exposure the medium 
was removed, cells were resuspended in 100 µl of RPMI 1640 with 10% FBS, 
and ATP released using 100µl nucleotide releasing reagent. After incubation 
at room temperature for 5 minutes plates were carefully mixed and 180µl
transferred to opaque white walled microtitre plates.  ATP concentration 
was determined immediately using a bioluminescence method.  Results 
were expressed as % luminescence relative to control  (untreated wells)
and the EC50 concentration calculated using Graphpad Prism software. The 
method was reproducible (e.g. EC50 for etoposide and dexamethasone in a 
sample analysed 5 times 1.26 ± 0.38 and 0.018 ± 0.004 µg/mL respectively).
Additionally, comparable results were obtained for samples analysed from 
frozen compared to the same sample analysed as fresh blasts in a different 
laboratory2 y2 y  (e.g. EC50 for etoposide in 3 samples 1.26 vs. 1.30, 0.95 vs. 0.98 
and 1.65 vs. 1.21 µg/mL).  The method is now being used to determine 
chemosensitivity to a panel of established and novel agents in a paediatric 
leukaemia study.
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FIBULIN-1 AND -4 MRNA EXPRESSION LEVELS IN HUMAN
COLORECTAL CANCER
IM Nolan, EJ Fox, C Moss, DT Leahy, R Geraghty, HE Mulcahy,
JP Hyland, D Fennelly, K Sheahan, D O’Donoghue, WS Argraves,
WM Gallagher 
1 United Kingdom, Department of Pharmacology, Department of Pathology 
and Core Technology Group, Conway Institute of Biomolecular and 
Biomediclal Research, University College Dublin, Dublin, 2 Ireland, Centre 
for Colorectal Disease, St. Vincent’s University Hospital, Dublin, 3 Ireland,
Department of Cell Biology and Anatomy, Medical University of South 
Carolina, South Carolina
The sequential progression of colorectal cancer offers unique possibilities for
studying the genetic changes involved in tumour progression. In this study,
we investigated the expression of two members of the ﬁ  bulin family (ﬁ  bulin-
1 and -4) in colon cancer. Different ﬁ  bulin variants demonstrate different
roles in cancer and can act as either oncogenes or tumour suppressor genes.
The aim of this work was to assess ﬁ  bulin-1 and -4 mRNA expression, using
TaqMan Real-time PCR assays (ABI Prism 7700 SDS), in a large panel of
colon tumour versus matched normal tissues with a view to determining
associations with tumour development and progression along with
clinicopathological variables. In addition we have assessed ﬁ  bulin-1 and -4
expression patterns in a large panel of tumour- and normal- derived cell lines
from different tissues origins.
Our biopsy study revealed an increase in ﬁ  bulin-4 expression (P=0.003,
n=40 patients, Matched Wilcoxan test) in tumour samples compared to the
corresponding matched normal tissue.  When correlated with patient proﬁ  les,
the comparisons that approached clinical signiﬁ  cance were observed between
increased ﬁ  bulin-4 expression and lower polyp number (P=0.086, Wilcoxan
test), as well as lymphovascular invasion (P=0.08, Wilcoxan test). We also
noted a slight downregulation of ﬁ  bulin-1 mRNA expression in tumour
biopsies (n=38 patients, P=0.095, Matched Wilcoxan test).
These results conﬁ  rm an involvement of ﬁ  bulin family members in colon cancer. 
The expression of ﬁ  bulin-1 is probably dependent on which isoforms are expressed 
since we have  designed real-time PCR assays to detect  ﬁ  bulin-1C and  –1D 
isoforms speciﬁ  cally and are in the process of reassessing the expression patterns 
of these splice variants in the same colon tissue pairs.  We have also demonstrated 
elevated ﬁ  bulin-4 expression in tumour biopsies, which is in accordance with the 
candidate oncogenic role previously suggested for this gene.
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IDENTIFICATION AND CHARACTERISATION OF PROTEINS
INTERACTING WITH HUMAN DNA TOPOISOMERASE I
A McNamara, AJM Watson, JR Jenkins
United Kingdom, University of Liverpool, Liverpool
Background: Human topoisomerase I (Top I) is of considerable
biomedical importance because it is the target of the camptothecin
(CPT) family of anticancer drugs.  Derivatives of CPT, irinotecan
and topotecan are routinely used in clinic, primarily in the treatment
of metastatic colorectal cancer.   The aim of this study is to identify
novel proteins interacting with Top I, which may reveal new potential
chemotherapeutic targets.
Methods:  Proteins that interact with Top I were identiﬁ  ed  using
extracts from the human colon adenoma HCT116 cell line by
immunoprecipitation, followed by mass spec (MALDI-TOF) analysis.
Interactions were conﬁ  rmed by counter immunoprecipitation.
Results: To date eighteen proteins have been identiﬁ  ed as physically
interacting with Top I.  One of these is Hsp70, which is known to be
associated with Top I.  Seven of these interactions have been conﬁ  rmed,
which include the molecular chaperone Hsp90.  This is the target of 
new up and coming anti cancer therapies.  Using the Hsp90 inhibitor 
geldanamycin (GA) on the HCT116 cell line, we have disrupted the
Top I and Hsp90 interaction.  Upon addition of a Top I poison we see
a synergistic effect on both cell killing and proliferation inhibition.
Surprisingly we have also demonstrated that up to 48 hours after GA
treatment Top I is not degraded.  This is despite the fact that GA binding
is thought to promote assembly of a super chaperone machine that
favours client protein degradation (Scheider et al 1996).
Conclusion: We have identiﬁ   ed a direct interaction between Top I 
and Hsp90, and found the combination of GA and Top I poisons act 
synergistically to both inhibit the growth of and kill colorectal cancer cells.
Continuing Work: Elucidation of the mechanism behind the
synergistic effect observed when Top I and Hsp90 inhibitors are used 
in combination.
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QUANTITATIVE TRAIT LOCUS ANALYSIS REVEALS TWO
INTRAGENIC SITES THAT INFLUENCE O6-ALKYLGUANINE-
DNA ALKYLTRANSFERASE ACTIVITY IN PERIPHERAL
BLOOD MONONUCLEAR CELLS
GP Margison, J Heighway, SJ Pearson, AC Povey, MF Santibáñez Koref6
United Kingdom, Institute of Human Genetics, University of Newcastle,
Newcastle
The repair of speciﬁ  c types of DNA alkylation damage by O6-alkylguanine-
DNA alkyltransferase (MGMT) is a major mechanism of resistance to the
carcinogenic and chemotherapeutic effects of certain alkylating agents. The
levels of expression of MGMT normal and tumour tissues are thus of interest
in relation to the prevention and treatment of cancer. MGMT expression in
a given tissue varies widely between individuals but the underlying causes
of this variability are not known. Here we investigate the contribution of
variation at the DNA level on intra-individual differences in MGMT activity
in peripheral blood mononuclear cells (PBMC). First we use an expressed
single nucleotide polymorphism (SNP) to demonstrate that the two MGMT
alleles are frequently expressed at different levels in PBMC, suggesting
that there is a genetic component of inter-individual variation of MGMT
levels that maps close to or within the MGMT locus. Next, we show by
quantitative trait locus analysis using intragenic SNPs that there are at least
two sites inﬂ  uencing interindividual variation in MGMT activity in PBMC.
One of these sites is characterized by an SNP at the 3’ end of the ﬁ  rst intron
and the second by two SNPs in the last exon. The latter two are in perfect
disequilibrium and result both in amino acid substitutions; one of them,
Ile143Val,  affecting an amino acid close to the cysteine (145) residue at
the active site of MGMT. In vitro assays did not reveal any inﬂ  uence of the
amino acid substitutions on the activity of the protein on methylated DNA
substrate, however, the Val143 variant was more resistant to inactivation by
the MGMT inactivator O6-(4-bromothenyl)guanine. Finally, the relationship
between alleles at the two sites and MGMT expression levels allows the
prediction of MGMT activity in individuals according to their genotype and
we report the results from a case-control series suggesting a link between
MGMT activity and lung cancer risk.
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COMPLEX PHENOTYPES ASSOCIATED WITH URACIL IN DNA 
IN MAMMALS
H Nilsen 1, Q An 1, J Fitzgibbon 2, A Lister 2, T Lindahl 1
1 Belgium, Cancer Research UK, London Research Institutes, Clare
Hall Laboratories, South Mimms, Herts, 2 United Kingdom, Cancer 
Research UK, Barts Medical Oncology Unit, St Bartholomew’s
Hospital, London
Deamination of cytosine, either of spontaneous origin or enzymatically
induced, leads to the generation of U:G mismatches in DNA, that upon
replication will lead to the formation of a C to T transition mutation
in one daughter strand. On the other hand, misincorporation of dUMP
into DNA during semiconservative replication leads to the formation
of U:A base pairs, lesions that are neither cytotoxic nor mutagenic.
We have observed an increased steady-state level of uracil in DNA
in gene-targeted mice deﬁ  cient in the Ung uracil-DNA glycosylase,
so Ung is the major enzyme removing uracil residues from U:A
base pairs. The absence of a generalised mutator phenotype in ung- g- g
/- mice indicated that complementary uracil-DNA glycosylases were
responsible for the removal of uracil from U:G base pairs resulting from
spontaneous deamination of cytosine in the general genome. However,
Ung has recently been shown to have a speciﬁ  c role in processing U:
G base pairs generated by enzymatic deamination of cytosine by AID
(activation-induced deaminase) during class-switch recombination and 
somatic hypermutation. We have found that aging Ung-deﬁ  cient mice
develop B-cell lymphomas. Our data therefore suggest that Ung is a
murine tumour suppressor gene. We are analysing genome instability
in Ung-deﬁ  cient murine tumours to attempt to unravel the molecular 
mechanisms underlying lymphomagenesis in ung-/- g-/- g  mice. We are also
extending the work to human tumour material in order to clarify if 
there is an occasional contribution of UNG-deﬁ  ciency in human B-cell
lymphomas.
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THE ROLE OF TUMOUR ENDOTHELIAL MARKER-8 (TEM-8)
IN HUMAN COLON CANCER AND ITS CORRELATION WITH
PROGNOSIS
Khaled Rmali, M CA Puntis, Wen G Janig 
United Kingdom, Department of Surgery, University of Wales College of 
Medicine, Cardiff
Background: TEM-8 is considered to be amongst several genes elevated
only in human tumour endothelium. However, little is known about its role
in solid tumours including colon cancer. This study sought to examine the
levels of expression for TEM-8 in human colon cancer and correlate it with
tumour prognosis.
Methodology:
Cancer and normal colorectal samples were obtained after surgery.  RNA
was extracted from frozen sections for gene ampliﬁ  cation.  The expression
of TEM-8 was assessed using RT-PCR, and the quantity of their transcripts
was  determined using real-time-quantitative PCR (Q-RT-PCR). Due
to the generation of TEM-8 antibody in our lab, for the ﬁ  rst time the
level of expression of TEM-8 examined at protein level using Western
blotting. Blood vessels and colon tissues (normal and cancer) were stained
immunohistochemically using anti-vonWillebrand Factor and anti-TEM-8
antibodies respectively. Statistical analysis carried out using student t test.
Results:
TEM-8 expression was signiﬁ  cantly higher in the tumour tissues compared
to the normal colon mucosa (p=0.001), the transcripts of TEM-8 were higher
in patients with Duke C (p=0.04 vs Duke A). Malignant cells in tumour
tissues stained strongly positive to TEM-8 compared with the epithelial cells
in normal colon tissues, and a highly elevated number of strongly stained
vessels that are positive to TEM-8, but not for vonWillebrand Factor.
Conclusion:
The aberrant expression of TEM-8 in  invasive colon cancer could have
signiﬁ  cant prognostic and therapeutic implications. Measuring this molecule
in colon cancer tissues may provide, for the ﬁ  rst time, important molecular
indicators of tumour differentiation, aggressiveness and prognosis.
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SODIUM SALICYLATE INHIBITS INFLAMMATION INDUCED
INVASION AND MIGRATION OF HUMAN MELANOMA CELLS
E Katerinaki 1, R Lalla 1, JW Haycock 1, PC Lorigan 2, S MacNeil 1
1 Department of Engineering Materials, University of Shefﬁ  eld, Shefﬁ  eld, 
United Kingdom, 2 Department of Medical Oncology, Christie Hospital, 
Manchester, United Kingdom
We have previously shown that TNF-alpha upregulates human melanoma cell
integrin expression, migration and invasion in vitro (1, 2). The aim of the current 
study was to investigate the effect of the non-steroidal anti-inﬂ  ammatory agent 
sodium salicylate on TNF-alpha induced activation of the transcription factor 
NFkappaB and on migration and invasion of melanoma cells.
HBL human melanoma cells were pre-incubated with sodium salicylate
at concentrations ranging between 0.1 and 5 mM prior to stimulation
with TNF-alpha at 200 units/ml  for 24 hours. NFkappaB activation
was measured using an assay that detects changes in the expression
of a luciferase reporter gene under the  direct control o f NFkappaB
transcriptional activity. The effect of sodium salicylate (5 mM) and TNF-
alpha (200 units/ml) on HBL cell invasion over 20 hours and migration
over 24 hours were studied using ﬁ  bronectin invasion and “scratch wound”
migration models in vitro as described previously (2).
Sodium salicylate inhibited TNF-alpha stimulated NFkappaB activation in 
melanoma cells in a concentration-dependent manner. The maximum effect 
observed was at a salicylate concentration of 5 mM that decreased TNF-
alpha stimulated activation of NFkappaB by 32% (n=3, p<0.01). Time course 
experiments showed that this effect was achieved with pre-incubation times 
as short as 15 minutes (28% inhibition). In functional assays TNF-alpha 
stimulated HBL cell migration on tissue culture polystyrene and invasion 
through ﬁ  bronectin were completely inhibited by sodium salicylate. 
In conclusion, sodium salicylate effectively inhibited TNF-alpha induced 
upregulation of gene transcriptional activity, in vitromigration and invasion
in human melanoma cells, indicating that non-steroidal anti-inﬂ  ammatory
drugs may  be a useful t herapeutic approach to oppose inﬂ  ammation
induced melanoma invasion and metastasis in vivo.
(1) Zhu N et al. J Invest Dermatol 2002; 119:1165-1171 l
(2) Katerinaki E et al. Br J Cancer 2003; 89: 1123-1129 r
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5T4 ONCOFOETAL ANTIGEN HETEROLOGOUS PRIME-BOOST 
WITH E1 DELETED ADENOVIRUS AND DENDRITIC
CELLS INDUCES SPECIFIC CD8+T CELLS AND TUMOUR 
IMMUNITY
S Ali, K Mulryan, T Taher, P.L Stern 
United Kingdom, Paterson institute of Cancer Research,
Manchester
5T4 is an oncofoetal antigen, discovered by looking for molecules
shared by human trophoblast and cancer cells. It is expressed by  a
wide spectrum of tumours but with restricted normal tissue expression.
In colorectal, gastric and ovarian cancer 5T4 tumour expression is
associated with poor clinical outcome.  The restricted adult tissue but
high frequency and cell surface expression by multiple carcinoma
types makes 5T4 antigen an attractive target for both antibody and
cell mediated immunotherapies. Early tumour studies using MVA
as a gene therapy vector have established the potential for 5T4 as an
immunotherapeutic target and have led to its translation into clinical
trial (Mulryan et al., Mol Cancer Ther 2002; 1: 1129-37). We have now
shown that E1 deleted recombinant adenoviruses expressing 5T4 are
effective gene therapy vectors for the induction of speciﬁ  c CD8 T cells.
A limitation to the use of any viral vector would be the presence of
pre-existing neutralising antibodies as well as generation of anti-viral
cellular immunity. Production of a maximal immune response can be
facilitated by a prime heterologous boost approach to vaccination. We
have developed 5T4 retrovirally transduced DC based carriers and used
them in combination with the adenoviral vectors. We show that such
heterologous prime boost regimens are highly efﬁ  cient in increasing
the 5T4-speciﬁ  c CD8+ T cell response. They provide increased survival
of mice from tumour growth in both protection and active therapy
assays.  We also show that the order of the heterologous prime –boost
immunisations can inﬂ  uence long term tumour immunity.
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DEVELOPMENT OF A CANCER VACCINE TARGETING 
COMPLEMENT REGULATORY PROTEIN CD55
RG Bradley, JM Ramage, R Metheringham, I Spendlove, LG Durrant 
United Kingdom, University of Nottingham, Nottingham
CD55 is one of several complement regulatory proteins (CRP’s)
involved in protection from autologous complement ‘bystander’ attack.
Expression of the CRP’s has been shown to be deregulated in a variety
of tumours with CD55 being up-regulated up to 100 times normal
levels.  This has been identiﬁ  ed as a signiﬁ  cant mechanism for evading
immune effectors by tumours and their microenvironment.  A cancer 
vaccine speciﬁ  cally targeting this associated antigen could be used to
promote existing humoral responses and to induce cytotoxic cellular 
mechanisms vital for tumour therapy. 
Utilising known algorithms for the prediction of HLA-A2 epitopes we
identiﬁ  ed sequences from within CD55 and modiﬁ  ed known anchor 
residues to enhance binding to MHC molecules.  These CD8+ peptides
were synthesised and epitope modiﬁ  cation was conﬁ  rmed via MHC
stabilisation assay on T2 cells.  These enhanced epitopes have  been
incorporated into CD55 (DNA)-Fc constructs and used with Helios
Gene Gun technology to immunise HLA-A2 transgenic mice.  This
strategy enabled in vivo expression of CD55-Fc protein containing our 
modiﬁ  ed residues.  One of these epitope enhanced constructs generated 
a  frequency of  1 cell in 5 x 103  IFNγ secreting cells speciﬁ  c to both γ
native and modiﬁ  ed peptides as demonstrated by ELISPOT analysis.
These  ﬁ   ndings were further elucidated by the presence of epitope
speciﬁ  c CTL responses to T2 targets pulsed with both modiﬁ  ed and 
native epitopes as assessed by 51Cr release.  Our ﬁ  ndings indicate that
modiﬁ  cation of anchor residues can enhance epitope speciﬁ  c responses
that recognise native sequences, indicating that the target epitope is not
lost during modiﬁ  cation. 
These results suggest the presence of a T cell repertoire speciﬁ  c for 
CD55 and t he efﬁ  cacy  of t his vaccine will  be assessed  in tumour 
models.  This strategy provides a novel approach for the development
of a cancer vaccine.
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PALMITOYLATION OF MT1-MMP AT CYSTEINE574 IN THE 
CYTOPLASMIC TAIL FACILITATES ITS INTERNALISATION 
AND MODULATE CELL MIGRATION
N Anilkumer, T Uekita, J Couchman, M Seiki, H Nagase, Y Itoh 
1 United Kingdom, Imperial College London, London,
2 United Kingdom, University of Tokyo, Tokyo
Membrane type 1 matrix metalloproteinase (MT1-MMP) is a type 1
transmembrane proteinase that promotes cell migration and invasion by
degrading components of the extracellular matrix and processing various
membrane proteins. MT1-MMP has a short cytoplasmic tail of 20 amino
acids which has been shown to direct internalisation of the enzyme via
incorporation into clathrin-coated pits. This occurs through interaction of
the Leu-Leu-Tyr573 motif of the cytoplasmic domain with the µ2 subunit
of Adapter Protein-2 (AP-2). Immediately downstream of the Leu-Leu-
Tyr573 motif, there is a Cys574which is a potential palmitoylation site as
it is located 12 amino acids away from the membrane proximal region.
Thus in this study, we investigated the palmitoylation of MT1-MMP
and its effects on the biological function of the enzyme. Palmitoylation
of MT1-MMP was studied using metabolic labelling of transiently
transfected COS-7 cells with [3H]palmitic acid, followed by immuno-
precipitation and autoradiography. The data indicated that MT1-MMP
is palmitoylated at Cys574 in the cytoplasmic  domain as Cys574Ala
or Ser mutant was not palmytoylated. Palmitoylation of the enzyme
was found to be critical for its rapid internalisation, though it did not
appear to affect the localisation of MT1-MMP to lipid rafts. Analysis
of further mutant molecules suggested that palmitoylation facilitates
the clathrin-mediated internalisation of the enzyme, by positioning
the Leu-Leu-Tyr573 sequence closer to the plasma membrane thereby
facilitating its interaction with AP-2 and subsequent incorporation into
clathrin-coated pits.
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ONCOSTATIN M-SPECIFIC SIGNALLING EVENTS INVOLVED
IN BIOLOGICAL RESPONSES OF T47D BREAST TUMOUR 
CELLS
N Underhill-Day, JK Heath
United Kingdom, University of Birmingham, Birmingham
Oncostatin M (OSM) is a member of the interleukin-6 (IL-6) cytokine
family which use a common signal-transducing receptor subunit,
gp130. OSM acts on target cells through interactions with either the
gp130/LIFRα receptor complex, also utilised by LIF, or the gp130/
OSMRβ receptor heterocomplex, speciﬁ  c to OSM. Formation of these
high afﬁ  nity receptor complexes results in activation of JAK/STAT and 
MAPK signalling pathways.
Oncostatin M is of particular interest due to its potent ability to initiate
differentiation and inhibit the growth of various human, tumour-derived 
cell lines. However, it is unclear to what extent the different receptor 
complexes contribute to these biological outcomes. The molecular 
interactions that underlie OSM-induced cytostatic and morphological
effects have not yet been resolved. 
In this study we used breast tumour-derived cell lines to compare
STAT & MAPK activation and downstream biological effects resulting
from ligand-induced stimulation of the representative hetero- and 
homodimeric receptor complexes (i.e. gp130/LIFRα, gp130/OSMRβ
and gp130/gp130). We found, through LIFRα antagonism in conjunction
with OSM exposure, that the potent cytostatic and morphological effects
of OSM on breast tumour cell lines are mediated through the gp130/
OSMRβ complex and not the gp130/LIFRα complex. Stimulation
with OSM, LIF and IL-6 initiated differential molecular proﬁ  les of 
STAT and MAPK pathway activation. In particular, OSM proved to
be a potent activator of JNK/SAPK and JNK-activated transcription
factors. Stimulation with OSM in the presence of an inhibitor of JNK 
serine/threonine kinase blocked OSM-induced morphological changes
revealing an important role for JNK/SAPK in OSM-induced cytostatic
speciﬁ  city.
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EPIDERMAL GROWTH FACTOR RECEPTOR TRAFFICKING BY 
SYNTAXIN
S Saxena 1, R Kharidia 1, S Cemeller 1, M Singh 1, S Kaur 1,
A Saxena 2
1 United States, Stevens Institute of Technology, Hoboken,
2 United States, Robertwood Johnson Medical School,
New Brunswick
Epidermal growth factor (EGF) receptors (EGFRs) belongs to tyrosine
kinase receptor family and are involved in signal transduction and
the regulation of cellular proliferation and differentiation of variety
of cancers, including those of the lung, breast and ovary. Although
members of the EGF receptor family are found predominantly at the
cell surface, these receptors also undergo constant cycling between
the plasma membrane and the endosomal compartment. Syntaxins and
vesicle-associated membrane protein (VAMP) families, also known as
soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein
receptors  (SNARE), have been implicated in mediating membrane
fusion and may play a role in determining the speciﬁ  city of vesicular
trafﬁ  cking. Syntaxins play a general role in membrane trafﬁ  cking by
acting as target membrane-speciﬁ  c receptors for transport vesicles. Our
studies suggest that EGF receptor interacts with syntaxin, a t-SNARE
through protein-protein interaction. We used syntaxin antibody to pull
down EGF receptor from pancreatic cancer cells, miapaca, induced with
epidermal growth factor. Alternatively, EGF receptor antibody pulled
down syntaxin and concomitant SNARE proteins involved in vesicular
trafﬁ  cking from cell homogenates.  EGF receptor expression can be
blocked by over-expressing ∆C syntaxin construct lacking membrane
binding domain. Moreover, syntaxin over-expression modulates
cellular proliferation. These data indicate towards the role of
syntaxin in regulation of EGF receptor trafﬁ  cking and possibly receptor
signaling.
Posters
S72
British Journal of Cancer (2004) 91(Suppl1), S24–S80 & 2004 Cancer Research UKP157:6
DEVELOPMENT OF A PREDICTIVE RISK ASSESSMENT
MODEL FOR DIET RELATED CHEMICALS USING COLONIC
CRYPT STEM CELL MUTATION INDICES  
ET Donnelly 1, H Bardwell 2, GA Thomas 2, ED Williams 2, M Hoper 1,
P Crowe 1, WG McCluggage 3, M Stevenson 4, DH Philips 5, A Hewer 5,
M Osborne 5, FC Campbell 1
1 United States, Surgery, Cancer Centre, The Queen’s University of 
Belfast, Belfast, 2 United Kingdom, Strangeways Research Laboratories,
University of Cambridge, Cambridge, 3 United Kingdom, Pathology,
School of Medicine, The Queen’s University of Belfast, Belfast, 4 United 
Kingdom, Epidemiology, School of Medicine, The Queen’s University of 
Belfast, Belfast, 5 United Kingdom, Section of Molecular Carcinogenesis,
Institute of Cancer Research, Surrey
Background:  Humans are exposed to complex mixtures of dietary
chemicals that may be implicated in colorectal cancer (CRC) but risk 
assessment is hampered by the lack of a mechanistically based predictive
model.  We test the hypothesis that colonic crypt stem cell mutation indices
(CCSCMI) including total mutation load, mutant patch formation and 
mutation frequency, may provide the scientiﬁ  c basis for a novel model.
Methods:  N-methyl-N-nitrosourea (MNU) and undegraded lambda
carrageenan (λCgN) were tested as model chemicals alone or within a
mixture, upon CCSCMI in 90 female Balb/c mice.  The predictive power 
of CCSCMI was tested against early tumour development, represented by
aberrant crypt foci (ACF), at 20 weeks after the start of treatment.
Results:  Combined λCgN/MNU treatment regimens were associated with
greater total crypt stem cell mutation load (p<0.01), greater mutant patch
formation (p<0.05), greater numbers of large mutant patches (≥ 3 mutant
crypts; p=0.002), greater number (p<0.001) and size (p<0.01) of aberrant
crypt foci, than MNU alone.  Linear correlations were observed between
total crypt stem cell mutation load, number (r=0.732; p<0.01) and size (r =
0.84; p<0.01) of aberrant crypt foci, in murine colon.
Conclusions: This study has developed and tested a risk assessment model
based on CCSCMI that appears suitable for risk assessment of dietary chemical
mixtures.  The model reﬂ  ects exposure patterns, improves understanding of 
interactive mechanisms and predicts early tumour formation.  This model may 
be useful for evaluation of chemopreventive therapy.
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CELL CYCLE DEPENDENT CHROMATIN PROTEOMICS:
IDENTIFICATION AND PRELIMINARY CHARACTERISATION
OF NOVEL CHROMOSOME BINDING PROTEINS
I.M Porter 1, G.A Khoudoli 1, J.S Andersen 2, J.J Blow 1, J.R Swedlow 1
1 United Kingdom, University of Dundee, Dundee, 2 United Kingdom,
University of Southern Denmark, Odense
Many important events of the cell cycle directly involve chromatin
and chromosomes.  These include chromosome replication, nuclear
assembly and reassembly, chromosome condensation and apoptosis.
Some of the protein factors involved in these processes are known, but
a full analysis of their cell-cycle dependent chromatin association has
not been achieved.  Many more factors likely remain to be identiﬁ  ed
and studied.
We have examined the proteome of chromatin and chromosomes at
speciﬁ   c stages of the cell cycle. Interphase chromatin and mitotic
chromosomes were generated in vitro by incubating sperm nuclei in
Xenopus egg cytoplasmic extracts.  After isolation of chromatin and
chromosomes, associated  proteins were eluted and soluble  protein
fractions were subjected to LC/LC-MS/MS or 2D gel electrophoretic
analysis.  
LC/LC-MS/MS analysis identiﬁ  ed over 450 chromatin bound proteins,
with 150 common to mitotic chromosomes and interphase chromatin.
Of 68 proteins of unknown function 22 were identiﬁ  ed as orthologues
of human proteins.  We have developed an siRNA-based microscopic
screen to characterise the properties of these proteins and have validated
the approach with six candidate proteins.  When depleted from cells,
each of these proteins causes signiﬁ  cant defects in mitotic progression. 
In addition, quantitative 2D gel comparison of soluble chromatin
fractions isolated at different stages of G1 and S-phase has revealed
approximately 50 proteins which have altered afﬁ  nity for chromatin
throughout DNA replication, including a number of previously
uncharacterised proteins.  Functional analysis of t hese proteins  is
underway.
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ETS GENE, PEA3 COOPERATES WITH Β-CATENIN-LEF-1 AND
C-JUN IN REGULATION OF OSTEOPONTIN TRANSCRIPTION
M El-Tanani 1, A Platt-Higgins 2, P.S Rudland 2, F.C Campbell 1
1 Denmark, Surgery, Cancer Centre, The Queen’s University of Belfast, 
Belfast, 2 United Kingdom, Cancer and Polio Research Laboratories,
School of Biological Sciences, University of Liverpool, Liverpool
Introduction: Upregulation of osteopontin (OPN) is a central event
of neoplastic transformation, colorectal cancer (CRC) metastasis and 
prognosis. OPN is not typically mutated and molecular mechanisms
responsible for its upregulation are unclear. The OPN promoter 
contains binding motifs for β-catenin-Tcf-lef-1, Ets and AP-1 which are
commonly disturbed during colorectal tumorigenesis.
Aim: We test the hypothesis that β-catenin-Tcf-lef-1, Ets and AP-1 signaling 
are implicated in combinatorial dysregulation of OPN transcription.
Methods:  Rama 37 epithelial cells were transiently co-transfected with 
wild type and mutant OPN promoter-luciferase reporter constructs mutated 
at Ets, Tcf and AP-1 binding domains. Effects of Ets factors, Ets-1, Ets-2, 
ERM and PEA3, as well as β-catenin, lef-1 and c-jun upon OPN-promoter 
luciferase activity and endogenous OPN expression were assessed. 
Results: β-catenin, Lef-1, Ets transcription factors and the AP-1
protein c-jun, each weakly enhanced luciferase expression from a OPN
promoter-luciferase reporter construct. OPN promoter responsiveness
to β-catenin and Lef-1, however, was considerably enhanced by Ets
transcription factors including Ets-1, Ets-2, ERM and particularly
PEA3. PEA3 also enhanced promoter responsiveness to the AP-1
protein, c-jun. Co-transfection of cells with β-catenin, Lef-1, PEA3 and 
c-jun in combination increased luciferase expression by up to 280 fold 
and induced expression of endogenous OPN.  
Conclusions: This study shows that β-catenin/Lef-1, Ets and AP-1
transcription factors can cooperate in stimulating transcription of OPN.
These transcription factors may be responsible for OPN over-expression
which is implicated neoplastic transformation CRC progression and 
metastasis.
P157:9
IDENTIFICATION OF THE COREGULATOR (S) THAT 
INTERACTS WITH THE OSTEOPONTIN PROTEIN IN THE
BREAST CANCER CELLS
D Jin, FC Campbell, M El-Tanani 
United Kingdom, Surgery, Cancer Centre, The Queen’s University of 
Belfast, Belfast
Introduction:
Osteopontin (OPN) is a multifunctional protein implicated in mammary
development, neoplastic change and metastasis. OPN is a target gene
for beta-catenin-Tcf signaling, which is commonly disturbed during
mammary oncogenesis but the understanding of OPN regulation is
incomplete. Coactivators and corepressors of OPN have not identiﬁ  ed,
little is known of its mechanism of action.
Methods:
Bacterial two-hybrid system has been used to isolate the cDNA
coding for a protein (s) (target proteins) that binds speciﬁ  cally to the
osteopontin  (bait protein). The mammalian two-hybrid system was
performed for protein-protein interaction conﬁ  rmation.
Results:
cDNAs codes for ﬁ  ve novel transcription factors (target genes) which
interacted speciﬁ  cally with OPN, have been isolated. These ﬁ  ve novel
genes have been accepted for Genbank publication. Their accession
numbers are AY562498, AY562499, AY562500, AY562501 and
AY562502.
Conclusions:
This study shows novel regulatory mechanisms of OPN transcription
involving 5 novel genes.  These novel mechanisms may be implicated in
OPN mediated neoplastic transformation.
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ACTIVATION OF HUMAN MONOCYTES VIA CD55 (DECAY 
ACCELERATING FACTOR)
HJ FitzGibbon, I Spendlove
United Kingdom, University of Nottingham, Nottingham
CD55 (also known as decay accelerating factor, DAF) is a glycosylpho
sphatidylinositol (GPI-)linked protein which acts to limit complement
deposition on cell surfaces.  It is found embedded in the membranes of 
most serum-exposed cells as well as being overexpressed by a range of 
solid tumours and deposited within tumour stroma.  However, tumour 
cell CD55 expression exceeds that required for maximal complement
regulation, suggesting that the molecule may have a role beyond that of 
a complement regulator within the tumour environment.  In support of 
this, studies have also reported that CD55 is able to act as a signalling
molecule.
Using ﬂ  ow cytometry, we have shown that stimulation of CD55 on
resting human monocytes, using the antibody 791T/36, results in the
upregulation of a number of surface molecules involved in antigen
presentation, such as the co-stimulatory molecules CD80 and CD86.
The changes in expression of the molecules analysed were similar 
to those observed upon lipopolysaccharide (LPS)-induced monocyte
activation, suggesting that stimulation of CD55 may be able to activate
the cells.
To show that these results were not due to LPS contamination of 
791T/36, we demonstrated an abrogation of these effects following heat
inactivation of the antibody at a temperature shown to have no effect on
the monocyte-activating ability of LPS.
These  ﬁ   ndings suggest that CD55 may be an important signalling
molecule on antigen-presenting cells and may have a co-stimulatory
role in the activation of T-cells.  To investigate this further we will be
assessing the cytokine proﬁ  le and effector function of CD55-stimulated 
monocytes.
P157:11
TRANSFECTION OF THE CHEMOKINE RECEPTOR CXCR4
ALTERS THE BEHAVIOR OF OVARIAN CANCER CELLS IN 
VITROAND IN VIVO
H Kulbe, JL Wilson, FR Balkwill 
United Kingdom, Cancer Research UK, London
The aim of this study was to understand the signiﬁ  cance of CXCR4
expression in ovarian cancer. Of 14 chemokine receptors investigated,
only CXCR4 was expressed by human ovarian cancer cell lines.
However, within ovarian tumor biopsies a minority of tumor cells
(1-20%) expressed CXCR4 mRNA. To clarify the role of CXCR4 in
ovarian cancer, we transfected the SKOV-3 cell line to produce two
different SKOV-X4 clones, with high CXCR4 expression, and mock
transfected lines, SKOV-M, with similar, low CXCR4 expression to
the  parental cell  line. Stimulation of SKOV-X4 cells with CXCL12
resulted in directed migration and invasion, proliferation under sub-
optimal growth conditions, increased adhesion to ﬁ  bronectin  and
induction of TNF-α mRNA.  Spheroids formed by SKOV-X4 cells were
smaller than those of SKOV-M, had less well deﬁ  ned borders and were
more spread. Mice injected with SKOV-M cells were killed between 4
and 10 weeks due to peritoneal disease, whereas those injected with
SKOV-X4 survived for a median of 12 weeks. Although the volume of
SKOV-X4 tumor was smaller in the abdominal cavity there were more
invasive and metastatic foci at distant sites. SKOV-M tumor deposits
surrounded the liver, spleen and omentum whereas SKOV-X4 deposits
were widely disseminated into the mesenteric tissue, ovaries, lymph
nodes, pancreas, thoracic cavity, lungs, and colon.  SKOV-M tumors
had better histological differentiation, lower mitotic index and did
not invade tissues.  SKOV-X4 tumors were highly invasive, with poor
histological differentiation and higher mitotic index. Thus, enhanced
CXCR4 expression results  in an ovarian tumor cell w ith a ltered
adhesive capacity and a more invasive phenotype.
P157:12
ESTABLISHING CELLULAR MODEL FOR STUDYING THE
CARCINOGENESIS OF HUMAN OVARIAN EPITHELIUM
N Li, G Wilbanks, D Dafou, I Jacobs, F Balkwill, S Gayther 
United States, Bart’s and The London, Queen Mary’s Medical School, 
London
Approximately 90 % of malignant ovarian tumours are epithelial and thought 
to arise from a single cell layer, the ovarian surface epithelium (OSE). In 
culture, human normal OSE cells have a very limited lifespan before they 
senesce, rarely progressing beyond 10 population doublings. This has 
restricted the use of normal ovarian surface epithelial cells (NOSE cells)
for identifying molecular events in vitro that may contribute to malignant 
transformation. We have investigated the conditions for culturing human 
NOSE cells in vitro using modiﬁ  ed medium supplemented with epidermal 
growth  factor  (EGF),  hydrocortisone  (HC),  insulin and  bovine pituitary 
extract (BPE) – NOSE CM medium. NOSE CM medium signiﬁ  cantly 
improved the seeding and cloning efﬁ  ciencies, overall cell growth and life 
span compared to culturing  in previously established non supplemented 
medium. Furthermore, these improvements in cell growth in NOSE-CM 
occurred without  detrimental effects to the epithelial morphology of the 
cells. Based on this optimised culture condition, n, we used a retroviral vector 
introducing hTERT, a gene encoding the functional catalytic sub-unit of 
telomerase,  into NOSE cells and established  immortal  human normal 
ovarian surface epithelial cells (IOSE cells). The telomerase activation has 
been conﬁ  rmed by TRAP assay and the stable telomere length has been 
identiﬁ  ed. In vitro and in vivo growth patterns such as serum dependence, 
contact inhibition growth, anchorage dependence and tumourogenic ability 
in nude mice conﬁ  rmed the immortality of IOSE cells. Furthermore, these 
IOSE cells are transformed by fractional doses of γ-ray irradiation. The  γ-ray irradiation. The  γ
malignancy of cells during the whole transformation procedure are assessed 
by both in vitro and in vivo assays. The transformed ovarian surface epithelial 
cells (TOSE cells), together with the parental immortal cells (IOSE cells) 
and normal primary cells  (NOSE cells)  lineage  forms a cellular model 
which deliberates broad biological utilities and greatly enables the studies to 
determine the carcinogenesis of human ovarian surface epithelium.
P157:13
IN VITRO MODEL OF MALIGNANT TRANSFORMATION
FOR THE IDENTIFICATION OF GENES IN BREAST CANCER 
FORMATION
D Dafou 1, NF Li 1, DA Trott 2, IJ Jacobs 1, SA Gayther 1, RF Newbold1
1 United Kingdom, Barts and the Royal London School of Medicine, Queenmary 
University, Translational Oncology Laboratory, John Vane Science Building, 
EC1M 6BQ, London, 2 United Kingdom, Institute of Cancer Genetics and 
Pharmacogenomics, Brunel University, Uxbridge, UB8 3PH, London
Cancer is a multistep disease where by genetic and environmental factors
represent  important stages  in the promotion,  initiation and progression of
the disease. Cell lines derived from tumours have  been valuable tools for
investigating t he pathogenesis of cancer and possible therapeutic agents.
However, the delineation of the early events of initiation/promotion, using
such cell lines can be ambiguous.  Normal human primary cells derived from
the target tissue at risk for neoplastic transformation provides a novel approach
that can be used to study the mechanistics of cancer progression in vitro.
Establishing models to investigate multistep process of malignant transformation 
may enable the different stages of transformation to be isolated and studied in 
detail.  Cell lines derived from normal human primary cells can be analysed 
for alterations to their phenotype and  gene expression among t hem. This 
includes the analysis of genetic alterations and their association with different 
transformation levels, including key oncogenes (c-myc, erb-2, k-ras) and tumour 
suppressor genes (BRCA1, BRCA2, p53) involved in breast cancer.
We  have established such a model for breast cancer from primary human
mammary epithelial cells  (HMECs). Brieﬂ  y, normal HMECs have  been
successfully immortalised by over-expressing the catalytic subunit of the
enzyme telomerase (hTERT). The ‘immortal’ cell line has been subjected
to ﬁ  fteen fractions of ionising radiation (2 Gy per fraction). During the
irradiation process cell lines were established with ever increasing levels of
transformation and quantiﬁ  ed at the cellular (ie. anchorage independence,
foci formation), genetic (SKY-FISH) and molecular genetic level (real –time
RT-PCR). cDNA expression microarrays were used to compare and identify
patterns of gene expression of HMECs irradiated with 14  and 20 Gy dose of
irradiation respectively. This has lead to the identiﬁ  cation of genomic changes
that may be critical during breast carcinogenesis. These experiments, show
the fundamental importance of the use of in vitro  human cell systems for the
identiﬁ  cation of molecular markers in breast cancer formation.
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VALIDATION OF PHARMACODYNAMIC ASSAYS TO EVALUATE 
THE CLINICAL EFFICACY OF AN ANTISENSE TARGETED TO
THE XIAP INHIBITOR OF APOPTOSIS 
J Cummings 1, T H Ward 1, E LaCasse 2, M Dawson 1, O Denneny 1,
D McManus 2, J Durkin 2, M Ranson 3, C Dive 1
1 United Kingdom, Clinical and Experimental Pharmacology, Paterson 
Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow
Road, Manchester, 2 United Kingdom, Aegera Oncology Inc., Ottawa,
3 Canada, Department of Medical Oncology, Christie Hospital NHS Trust, 
Wilmslow Road, Manchester
XIAP  is a potent endogenous caspase inhibitor  frequently overexpressed in 
human tumours. Recently, a 19-mer second generation antisense oligonucleotide 
targeting XIAP has been approved for a Phase I Trial. Validation strategies and 
performance data on 3 different pharmacodynamic (PD) assays will be presented 
that will be utilised as endpoints during this trial. To facilitate validation, we 
employed a genetically-engineered cell line (MDA XG4) stably expressing a 
RNAi to silence XIAP as a negative control. Immunohistochemistry  (IHC) 
of XIAP in tumour biopsies was validated using sections prepared from ﬁ  xed 
pellets/tissues derived from XG4 cells and panel of cancer cell lines that represent 
a 3-4-fold dynamic range of XIAP protein expression.  These calibrators deﬁ  ned 
staining intensity levels against which the patient samples will be assessed. 
Studies were performed on within-day and between-day precision and on the 
stability of XIAP in the ﬁ  xed sections. The M30-ApoptosenseTM Elisa detects a 
caspase cleaved fragment of cytokeratin 18 that is released into the circulation 
after apoptotic cell death and is believed to represent a plasma surrogate marker 
enabling a quantitative assessment of apoptosis occurring  in the patient’s 
tumour. Validation of this technique focussed on generating an independent 
positive quality control to perform measurements on precision, kit-to-kit QC, 
and stability studies. Precision data obtained using this control ranged from 3.6-
6.7%. Kit to kit variability was less than 10%, while samples stored at –800C 
were demonstrated to be stable for at least two months. Western blotting of XIAP 
was validated using replicate frozen pellets of 1 negative and 2 positive control 
cell lines. XIAP was quantitated by densitometry as a ratio to GAPDH and by 
reference to a calibration curve constructed using recombinant XIAP protein. To 
determine the linearity and the dynamic range of the assay, increasing amounts 
of recombinant GST-XIAP or of the BIR3-RING fragment were added to lysates 
of the null cell line.
P159
DEVELOPMENT OF A CELL FREE SYSTEM TO IDENTIFY 
MOLECULAR CONNECTIONS BETWEEN DNA DAMAGE AND
APOPTOSIS IN CEM T LYMPHOMA CELLS
I Moteiro dos Santos Pires 1, SP JAckson 2, C Dive 1
1 United Kingdom, Paterson Institute for CAncer Research,
Manchester, 2 United Kingdom, Wellcome Trust/CAncer Research UK 
Gurdon Institute, Cambridge
Resistance to DNA damaging drugs is a formidable obstacle to 
chemotherapy approaches to disease treatment. This resistance is due, at 
least in part to an uncoupling of DNA damage signals to the engagement of 
apoptotic cell death. A cell free system has been developed in which isolated 
naïve mitochondria are incubated with a ‘drug activated’ cytosolic fraction 
in order to identify DNA damage signals that are conveyed to the apoptotic 
machinery at the mitochondrial surface. Treatment with the UV mimetic 4-
NQO (10 µM) resulted in the activation of CHK1 by 15 min whereas CHK2 
was not activated until 30 min. 4-NQO treatment resulted in 20% and 50% 
apoptotic cells at 4h and 8h respectively. A detailed examination of caspase 
activity was performed using a ﬂ  uorogenic assay in order to deﬁ  ne a time 
point after drug treatment at which DNA damage had been recognised 
and signalled (as indicated by activation of CHK2 or CHK1) and the 
damage signals generated could release cytochrome c upstream p of caspase  m
activation. The earliest time point at which cytochrome c releasing signals, 
generated by 4NQO mediated DNA damage, were present in cytosolic 
fractions was 4h. Cell free experiments were performed in the presence 
and absence of the pan caspase inhibitor ZVAD (100µM).  Cytochrome c 
was released from naïve mitochondria incubated with cytosols from cells 
treated for 4h with 4NQO regardless of caspase inhibition by ZVAD. The 
roles of Bax and Bak are now being investigated in this system as well as 
an examination of the levels and subcellular location of BH-3 only Bcl-2 
family members.  4-NQO activated, ZVAD treated cytosols will now be 
fractionated and the fractions applied to naïve mitochondria in order to 
identify the DNA damage mediated, caspase independent cytochrome c 
releasing signalling molecules.
P160
LYMPHOCYTE DEATH BY CATIONIC POLYMERS: A ROLE 
FOR MITOCHONDRION AND IMPLICATIONS IN GENE 
THERAPY
JC Murray 1, SM Moghimi 2, AC Hunter 2, P Symonds 1, G Debska 3,
A Szewczyk 3
1 United Kingdom, Wolfson Digestive Diseases Centre, University
Hospital, Nottingham, 2 United Kingdom, School of Pharmacy and 
Biomolecular Sciences, University of Brighton, Brighton, 3 United 
Kingdom, Nencki Institute of Experimental Biology, Polish Academy of 
Sciences, Warsaw
A wide range of synthetic polycations in linear, branched, or dendrimer form have 
been used to condense DNA into structures amenable to cellular internalization 
via endocytosis. Polycations can destabilize endosomal membranes or act 
as proton sponges; they buffer the low pH in the endosomes and potentially 
induce membrane rupture, resulting in the release of polycation/DNA complex 
into the cytoplasm. The polycationic nature of the gene-delivery vehicles can 
induce cytotoxicity, but the mechanisms are poorly understood. We studied the 
effect of a number of commonly used polycations on mitochondrial functions 
in isolated mitochondria from rat liver as well as directly in Jurkat cells. Upon 
permeabilization or rupture of the outer mitochondrial membrane, cytochrome 
c binds to Apaf-1, leading to allosteric activation of pro-caspase-9. This in turn  c
proteolytically activates caspase-3, one of the principal proteases that participates 
in the execution of cell death. A decrease in mitochondrial membrane potential 
(∆ϕ (∆ϕ ( ) due to permeability transition is also an early event in several types of 
apoptosis. We have demonstrated that at very low concentrations, polycations 
can affect mitochondrial respiration and ∆ϕ; these events were followed by 
cytochrome  c release from mitochondrial intermembrane in mitochondrial  c
suspensions and in Jurkat cells. Changes in mitochondrial ∆ϕ in Jurkat cells were  ϕ
conﬁ  rmed by the Mitosensor test. Detection of phosphatidylserine translocation 
to the cell surface and proteolytic activation of caspase-3 by apoptosome further 
conﬁ  rmed activation of apoptosis in Jurkat cells. These observations provide a 
molecular explanation for previously reported immediate or delayed cytotoxicity 
following gene transfer with polycations. The results from this study may help 
to design novel materials with high transfection efﬁ  ciencies suitable for clinical 
gene therapy.
P161
ETOPOSIDE INDUCED P53-DEPENDENT GENE EXPRESSION
IN COLON CANCER:  ANALYSIS OF BIRC3, A CANDIDATE
GENE
A. Davies, A.V . McNamara, A.J.M. Watson, J.R. Jenkins
United Kingdom, University of Liverpool, Liverpool
Background:  Loss of p53 tumour suppressor function is common to
most cancer types; and is a late stage event in colon cancer tumourgensis.
Etoposide (VP16) is a cytotoxic agent whose target is topoisomerase-II,
an enzyme vital for successful DNA replication.  Colon cancer responds
poorly to Vepesid (VP16) treatment and induces toxic side effects;
including the signiﬁ  cant risk of secondary leukaemia.  The aim of this
study was to identify novel p53-dependent genes involved in response
to VP16 treatment.
Methods:  Array Analysis of VP16 treated (50µM; 24hrs) human colon  µM; 24hrs) human colon  µ
adenoma HCT116 (p53 isogenic pair) cell lines was performed, and mRNA 
expression changes conﬁ  rmed by Real Time PCR (qPCR).  Protein expression 
was investigated by western blotting (WB) and immunocytoﬂ  uorescence
(ICF).  Small interfering RNAs (siRNA) were designed to create a transient 
BIRC3 “knock-down” cell type for clonogenic assays.
Results:  The Array Analysis identiﬁ  ed a member of the Inhibitor of
Apoptosis (IAP) family, Baculoviral IAP Repeat (BIRC3), which was
conﬁ  rmed by qPCR.  This gene exhibited a p53-dependent increase in
mRNA and protein (WB) expression following VP16 treatment.  ICF
showed a perinuclear cellular distribution.  In a BIRC3 siRNA “knock-
down” experiment on HCT116 cells, following treatment with VP16,
an increase in cell killing of 30% was observed when compared to the
mock-transfected cells.
Conclusion:  BIRC3 is a, VP16 responsive, p53-dependent gene in the
human HCT116 colon adenoma cell line.  The increased expression
of the Birc3 protein could be a contributory factor to an induced
apoptotic resistance in colon cancer. Other research groups have also
proposed that deregulation of another IAP family member, Survivin, as
a contributor towards the progression of colon cancer.
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4-HYDROXY(PHENYL)RETINAMIDE INDUCES APOPTOSIS IN 
THE EWING’S SARCOMA FAMILY TUMOURS (ESFT) THROUGH
A P38MAPK DEPENDENT PATHWAY K
SS Myatt, SA Burchill
United Kingdom, Candlelighter’s Research Laboratory, Leeds
4-hydroxy(phenyl)retinamide (4-HPR) is a promising anti-cancer 
agent, inducing cell death in a wide range of cancer cell types and with
low toxicity in paediatric  phase 1 clinical trials (Cancer Lett. (2003)
197(1-2):185-92). In this study the effect of 4-HPR on viable (trypan
blue exclusion assay) and apoptotic (annexin V/propidium iodide) cell
number in six ESFT cells lines has been evaluated. The role of p38MAPK
in the induction of cell death by 4-HPR has been investigated using
Western blots and inhibitors of  p38MAPK signalling (SB202190). K
4-HPR (0.75-10 µM) induced apoptosis in 6/6 ESFT cell lines within
24h exposure in a dose-dependent manner. PARP cleavage was
observed after 8h treatment of TC-32 cells with 4-HPR (1.5 µM).
ESFT TC-32 cells were more sensitive to 4-HPR-induced death than the
neuroblastoma SY5Y cell line; IC50 0.95µM and 5.3µM respectively.
This suggests a novel mechanism of 4-HPR action in ESFT. 
Consistent with previous studies in other cancer cell types, a dose-dependent 
increase in reactive oxygen species (ROS) was observed in TC-32 cells 
following treatment with 4-HPR. There was a 6-fold increase in ROS after 
1h exposure to 4-HPR, compared to a 3-fold increase in SY5Y cells. Pre-
treatment of TC-32 cells with the anti-oxidant ascorbic acid (100 µM, 1 h) 
prevented the accumulation of ROS and rescued 100% of TC-32 cells from 
4-HPR (1.5 µM) induced cell death. p38MAPKwas phosphorylated following  K
exposure of ESFT cells to 4-HPR. Inhibition of the p38MAPK pathway with  K
SB202190 (6.7 µM; 1h) rescued 52% of TC-32 cells from 4-HPR-induced 
death. This was accompanied by complete inhibition of PARP cleavage and 
partial reduction in ROS accumulation (25%).
In conclusion, 4-HPR induces apoptosis in all ESFT cells studied.
Activation of p38MAPK appears to play a role in 4-HPR-induced death K
in ESFT. This may in part explain the increased sensitivity of ESFT to
4-HPR compared to neuroblastoma cells.
P163
DOWNREGULATION OF BCL-XL EXPRESSION USING SIRNA
SENSITISES COLON CANCER CELLS TO TOPOISOMERASE I
INHIBITOR SN-38
ML Hua, P Kang, S Guichard, DI jodrell
University of Edinburgh, Edinburgh, United Kingdom
Apoptosis is the prevalent form of programmed cell death and
overexpression of anti-apoptotic  proteins like Bcl-2 and bcl-xl has
been linked to resistance to chemotherapeutic agents. RNA interference
using small interfering RNA (siRNA) has recently been developed to
speciﬁ  cally silence genes. We designed 4 different oligonucleotides (#1,
#2, #3 and #4) inserted in pSUPER-Neo-GFP vector to express short
hairpin RNA sequences targeting 4 different regions of bcl-xl mRNA.
We transfected 2 colon cancer cell lines, HCT-116 and HT-29 cells with
the 4 different constructs as well as the empty vector. We evaluated the
transfection efﬁ  ciency monitoring the GFP expression using ﬂ  uorescence
microscopy. HT-29 cells had very low transfection efﬁ   ciency so we
selected positive clones (geneticin-resistant) by growing cells in medium
containing 1000 µg/ml of geneticin. The growth rates of the different
isogenic cell lines stably transfected were similar with doubling times
ranging from 16 to 18h. We determined the level of bcl-xl expression in
the different clones by real-time RT-PCR using 2 different sets of primers.
18S rRNA expression was used as internal standard. In HCT-116 cells, the
level of bcl-xl expression normalized with 18S expression were 1 ± 0.1, 1
± 0.2, 0.6 ± 0.1, 0.7 ± 0.1, 0.5 ± 0.07 and 0.5 ± 0.15 in HCT-116 parental
cells, cells expressing the empty vector, #1, #2, #3 and #4, respectively so
2 out of 4 constructs had a bcl-xl expression signiﬁ  cantly lower than cells
transfected with the empty vector. We determined the growth inhibition
of the topoisomerase I inhibitor SN-38 in the different isogenic cell lines
using the sulforhodamine B assay. The IC50s using 24h-exposure were
4 ± 0.03, 4 ± 0.03, 2.8 ± 0.04, 3.2 ± 0.3, 1.8 ± 0.07 and 2.2 ± 0.07 nM
for HCT-116 parental, expressing the empty vector controls, #1, #2, #3
and #4, respectively. We plan to extend these results to HT-29 cells and
to investigate if the decrease in bcl-xl RNA levels is correlated with an
increase in apoptosis after exposure to SN-38.
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IMMUNOHISTOCHEMICAL DETECTION OF APOPTOTIC
MARKERS IN GASTRIC CANCER
L Smith, HK Berrieman, SL O’Kane, A Campbell, A Maraveyas,
L Cawkwell
PGMI, University of Hull, Hull, United Kingdom
Gastric cancer is the second most common malignancy worldwide
and prognosis remains poor. Treatment involves the administration of 
chemotherapeutic agents, which act to initiate apoptosis by inducing
irreparable DNA damage. Unfortunately, the objective response rate
remains low and such treatment, if not beneﬁ  cial for the patient, causes
needless toxicity and undesirable side effects. Effective treatment is
hampered by the tumours ability to exhibit various mechanisms of drug
resistance. Alterations in the expression of apoptosis-related proteins
may alter response to chemotherapy.
Immunohistochemistry was exploited in this pilot study to examine
a comprehensive panel of apoptotic biomarkers in 21 cases of gastric
cancer. This preliminary study was essential; biopsy samples taken on
diagnosis (pre-treatment) are small and not enough tissue is available
to test the entire panel of antibodies for heterogeneous expression. The
biomarkers selected for analysis were p53, p21, Fas, Bcl-2, Bax, Bcl-
xL, Bid, Bim, Bad and Bak. Aside from the well studied proteins, such
as p53 and Bcl-2, few of the apoptotic markers used in this study have
previously been analysed in relation to gastric cancer.
The expression of Bim, Bcl-xL and Bak was high (>75% of tumours
positive), the expression of Fas, Bax, Bad, p53 and p21 was intermediate
(25-75% positive) and Bid and Bcl-2 expression was low (<25%). In a
further study, those biomarkers selected from this study will be applied 
to biopsy samples and expression will be correlated with patient
response in an attempt to identify predictive markers.
It is hoped that in the future, biopsy samples taken on diagnosis will be
examined for the expression of such predictive markers. The prediction
of which therapeutic intervention will most likely beneﬁ  t a given patient
would reduce needless side effects and toxicity.
P165
APOPTOTIC PROTEIN EXPRESSION DIFFERS BETWEEN
NON-SMALL CELL LUNG CANCER SUB-TYPES
HK Berrieman, L Smith, SL O’Kane, A Campbell, MJ Lind,
L Cawkwell
PGMI, University of Hull, Hull, United Kingdom
The main form of treatment for inoperable non-small cell lung cancer
(NSCLC) is chemotherapy.  The status of the apoptosis pathways in
NSCLC cells may therefore be crucial for treatment outcome.  One
major group of proteins involved in the control of apoptosis is the Bcl-2
family of proteins, but except for Bcl-2 itself, little is known about the
expression of these potentially critical proteins in human cancers.  A
second group of proteins which may play important roles in apoptotic
pathways, but which have also not been extensively studied in cancer,
are the heat shock proteins (Hsps).
We have used immunohistochemistry to study the expression of Bcl-
2 family proteins and Hsps in a pilot series of 41 archival NSCLC
specimens.  Nineteen samples were adenocarcinomas (AC) and 22 were
squamous cell carcinomas (SCC).  Sections were scored as positive
or negative by two independent observers and associations between
variables tested using Chi-square analysis.
Bax (pro-apoptotic protein), Hsp70 and Hsp27 showed high expression
(>70% positive), Bak and Bid and Bad (all anti-apoptotic) showed
intermediate expression (50-70% positive), and the pro-apoptotic
proteins Bcl-2 and Bcl-XL showed low expression (<50% positive).
Certain proteins showed statistically signiﬁ   cant differences in
expression between AC and SCC samples.
Our results, although only a pilot study, reveal signiﬁ  cant differences in
the expression of apoptosis-related proteins both between individual cases
of NSCLC and also between the two main histological sub-types.  Such
differences could have major inﬂ  uence on not only the development of
these tumours but also their response to chemotherapy.  If such differences
prove to be of clinical importance it could require that NSCLC sub-types
be regarded as separate entities rather than as one disease.
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SPONTANEOUS AND DNA DAMAGE INDUCED APOPTOSIS IN A 
MODEL OF INTESTINAL EPITHELIAL REGENERATION
M Hoper 1, M O’Connor 1, ET Donnelly 1, S McCullough 2,
FC Campbell 1
1 United States, Surgery, Cancer Centre, The Queen’s University of 
Belfast, Belfast, 2 United Kingdom, Anatomy, School of Medicine,
The Queen’s University of Belfast, Belfast
Background: Renewal tissues have a stem cell hierarchy, capacity for 
regeneration and are the most frequent sites of mutagen induced tumour 
formation. Apoptosis provides an important defence against mutagen
induced cancer by elimination of  irretrievably  damaged cells. This
study tests the hypothesis that spontaneous and DNA damage induced 
apoptosis are suppressed in early regeneration which may facilitate
expansion of mutant epithelial clones.
Methods: Regeneration was induced in a model system by stem cell
grafting. Stem cell aggregates from neonatal rat small intestine were
implanted subcutaneously and regenerated intestinal mucosa with
complete crypt/villus architecture over 3 weeks. Grafts retrieved a t
7, 14 and 21 days represented early, intermediate and late stages of 
regeneration. To assess effects of regeneration stage on carcinogen
induced apoptosis, animals were treated by N-methyl N-nitrosourea
(MNU; 62.5mg/kg) vs saline control subcutaneously, 18 hours before
graft retrieval at 7, 14 or 21 days. Apoptosis was assessed by the TdT-
mediated dUTP nick-end labelling assay.
Results:  Carcinogen treatment promoted apoptosis in late regenerating
grafts at 3 weeks (Apoptosis - 10.6 ± 1.15% vs 6.1 ± 0.5% MNU treated 
vs untreated cells p<0.05). No evidence of an apoptosis response to
mutagen exposure was found in early regeneration. 
Conclusions: The apoptosis response to carcinogen treatment appears
to be suppressed in early regeneration. Early regeneration may thus
provide a window of susceptibility to carcinogen induced mutation.
P166
INCH: INDUCTION CHEMOTHERAPY AND CHART.
A RANDOMIZED PHASE II/III OF INDUCTION CHEMOTHERAPY
FOLLOWED BY CHART VERSES CHART ALONE IN PATIENTS WITH
NON-SMALL CELL LUNG CANCER
M Hatton, E Lyn, A Hodson, R Stephens 
1 Weston Park Hospital, Shefﬁ  eld, United Kingdom, 2 Mount Vernon Hospital,
London, United Kingdom, 3 Medical Research Council, London, United 
Kingdom, 4 Medical Research Council, London, United Kingdom
Introduction.
The published 2-year survival for CHART radiotherapy is comparable to that seen
with induction chemotherapy and conventionally fractionated radiotherapy. Initial
attempts to give induction chemotherapy with CHART have reported signiﬁ  cant
pulmonary toxicity.  More recent reports have conﬁ  rmed feasibility (1,2) and the
experience of the UK CHART centres indicate a rate of grade 3/4/5 pneumonitis
of 2 –3 %. (Personal Communication)
Aims.  
To compare 3 cycle of vinorelbine/cisplatin induction chemotherapy followed by
CHART radiotherapy with CHART radiotherapy alone. 
The primary endpoint is overall survival; measured secondary endpoints are
safety, toxicity, response rate, local control rate, progression free survival and
quality of life.
Treatment.
Induction Chemotherapy: Vinorelbine (30 mgs/m2) day 1 and 8; Cisplatin (80
mgs/m2) on day 1 of a three weekly cycle. Three cycles. 
CHART 54 Gy of thoracic irradiation in 36 fractions treating 3 times daily over
12 consecutive days.
Trial design.
A randomised, open, multi-centre, phase II/III study for patients with inoperable
NSCLC, good performance status and suitable for CHART radiotherapy.
A data monitoring committee will assess feasibility and safety after 80 patients
have been treated.
If an acceptable rate of toxicity is conﬁ  rmed the trial will continue to recruit to
500 patients, which will give a 90% power to detect a 50% improvement in 3-year
survival (from 10 to 15%). 
The INCH trial will open to recruitment in spring 2004.
1) Bell V , Falk S, Gee A. Clinical Oncology 2002;14;S28.
2) Saunders MI, Rojas A, Lyn E, et al. Clinical Oncology 2002;14:352-60.
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CLINICAL TRIAL PATIENT PATHWAY: MAKING THE PATIENT
JOURNEY LESS OF A TRIAL
C May, Northern Centre for Cancer Treatment, Newcastle General 
Hospital, Newcastle-upon-Tyne, United Kingdom
Background: To integrate clinical trials and related research into routine
care provision1.
Objective: To deﬁ  ne and describe a patient pathway for the enrolment of 
patients into a large phase III trial2.
Setting: Large cancer centre in England.
Method: Creation of a delineated patient journey from specialist centre
multi-disciplinary team meeting  (MDM) to commencement of trial
chemotherapy on day unit at cancer centre.
Mechanism: Acknowledging the difﬁ  culty of integrating research
with routine service provision; working collaboratively, inter-
professionally and inter-departmentally to create protocols and 
profroma; and acknowledging a clear, but compatible division of labour 
between research tasks and routine chemotherapy tasks within this
framework.
Outcome: Patient journey: MDM to commencement of treatment 17-
21 days (though not a ﬁ  xed timeframe, as ﬂ  exible enough to allow for 
patient choice3). Trial activities, with fully informed consent, completed 
within this timeframe and alongside routine treatment preparation,
thus incorporating effective provision of care for patients who decline
to participate in the trial. Standardised quality of care, and full
participation of the patient, who is enabled to make an informed choice
about her own pathway through treatment.
1. Department of Health, Sept 2000, The NHS Cancer Plan: a plan for 
investment a plan for reform, Topic 10
2. NHS Executive, Health Services Directive, The Manual of Cancer 
Service Standards, Topic 2
3. Department of Health, Sept 2000, The NHS Cancer Plan: a plan for 
investment a plan for reform, Topic 5
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THE ESTABLISHMENT OF A PORTFOLIO OF LIVER CANCER 
TRIALS WITHIN A UK CLINICAL TRIALS UNIT
DP Brant, JM Barnwell, JA Dunn, PJ Johnson 
Cancer Research UK Institute for Cancer Studies Clinical Trials Unit, 
Birmingham, United Kingdom
There are four main primary liver cancers, the most common being
hepatocellular carcinoma and cholangiocarcinoma or biliary tract
cancer.  The incidence of primary liver cancer has increased over
the last ten years with hepatocellular carcinoma doubling and
cholangiocarcinoma increasing 10 fold.  
Hepatocellular carcinoma is responsible for approximately 1500 deaths
per year in the UK. The only chance of cure is surgery, with few patients
being candidates. Currently there is no standard therapy for patients
with unresectable or recurrent hepatocellular carcinoma. The median
survival rate for these untreated patients reported as less than 2 months.
Cholangiocarcinoma is responsible for approximately 1000 deaths a
year in England and Wales. The majority are advanced at presentation
and of those patients that do proceed to potentially curative resection,
the majority relapse with advanced disease.
The Trials Unit currently has two multicentre trials in these two
common liver cancers. The hepatocellular carcinoma trial, HEP-1
is a NCRN trial funded by Cancer Research UK, and is due to start
recruitment in June 2004, and the biliary tract cancer trial, BILCAP will
be submitted as a full proposal to CTAAC for funding in June this year.
A major development from this is the successful bid by the Trials Unit
to run multi-centre controlled trials fostered by the British Association
for the Study of the Liver (BASL).   BASL is a large liver group with
approximately 400 members who promote communication between
British workers interested in the liver and its disorders. Through
collaboration with BASL the Trials Unit aims to establish a large
portfolio of liver cancer trials.
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CONSUMER INVOLVEMENT IN THE NATIONAL CANCER 
RESEARCH INSTITUTE (NCRI) AND THE NATIONAL CANCER 
RESEARCH NETWORK (NCRN)
T Stevens, R Wilson, M Stead 
NCRN, Leeds, United Kingdom
The Consumer Liaison Group (CLG) of the National Cancer Research
Institute (NCRI) is made up of patients carers and support group workers
who represent consumers on the 17 NCRI cancer site speciﬁ  c Clinical
Study Groups (CSGs) and the four cross-cutting CSGs. The role of 
consumers actively  involved  in cancer research  is rapidly evolving
from this starting position with the CLG taking a prominent role in
supporting a range of initiatives with the 34 English regional Cancer 
Research Networks coordinated by the National Cancer Research
Network (NCRN). Consumers are also becoming increasingly involved 
with the work of the Clinical Trials Units, the National Translational
Cancer Research Network (NTRAC), and the regional NTRAC Centres.
The role of Cancer  Voices and Macmillan Cancer Relief in these
initiatives has also been signiﬁ  cant. Consumer representation in cancer 
research takes patients and their supporters beyond lobbying or activism
into involvement with issues such as ethics, research management,
trials design and into evaluating the value of this involvement. The
poster maps the various consumer groups in cancer research and 
describes their relationships with the various regulatory, management
and voluntary organisations. Underpinning this work is a belief that
studies that consumers have helped design may be studies that patients
are more likely to enter. The formation of a new national infrastructure
to support research activity and provide a strategic overview of cancer 
research is providing a unique opportunity to extend and integrate the
scope of consumer involvement.
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GMCCRN ‘GREAT EXPECTATIONS’ ‘GREAT EXPERIENCES’
LE Turner 1, K Cox 2
1 Greater Manchester & Cheshire Cancer Research Network, 
Manchester, United Kingdom, 2 Greater Manchester & Cheshire
Cancer Research Network, Manchester, United Kingdom
Background: Mortality due to cancer accounts for 25% of men and
women in the Northwest. In order that advances in cancer management are
achieved more quickly there needs to be an increase in the level of cancer
patients being entered into clinical trials. However, it has been reported
that only 2-5% of eligible cancer patients participate in such trials. 
The  Greater Manchester  &  Cheshire  Cancer Research Network
(GMCCRN) is the largest network in the country with a population
of 3.2 million. Appointment of the research team, both research
nurses and c linical trial a dministrators  (CTAs) took p lace  from  7th
July to 4th November 2003. Within the networks’ 12 NHS trusts there
exists a research team to help set up cancer clinical trials, establish an
appropriate trial portfolio, support the recruitment and retention of trial
patients and act as patient advocate. Anecdotally, recruited patients
within GMCCRN have expressed that having a research nurse to manage
their care pathway through out a trial has been highly beneﬁ  cial.
Aim: To reach the national accrual proportion of 7.5% of all cancer
patients to be recruited into NCRN cancer clinical trials by March 2004.
Equating to 900 patients within GMCCRN. To carry out a retrospective
case study to examine patient’s attitudes and satisfaction in taking part
in a clinical trial.
Results: At the end of December 2003 the GMCCRN accrual data
showed an actual percentage of 6.32%. It is anticipated that the
GMCCRN is likely to meet and potentially exceed the 7.5% target.
Discussion: Our network clearly demonstrates an impact on the provision 
of clinical trials for cancer patients. Naturally, the size of the network and 
the diversity of experienced nurses with or without oncology and research 
background have played a huge role in the network’s success. How patients 
entering NCRN clinical trials perceive this impact, will be illustrated.
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FOLLOW UP AFTER COLORECTAL SURGERY
(THE FACS TRIAL)
A Corkhill 1, JN Primrose 1, D Mant 2, The FACS study group 1
1 University of Southampton, Southampton, United Kingdom,
2 University of Oxford, Oxford, United Kingdom
The value of follow up after potentially curative colorectal cancer 
surgery is uncertain although a number of underpowered studies point
to the potential value of CEA monitoring and cross sectional imaging.
The FACS trial aims to study 5000 patients randomised to one of 4
follow up strategies: Arm 1. Symptomatic follow up in primary care,
Arm2. CEA measurement in primary care, Arm 3. CT imaging based 
hospital follow up, Arm 4. Combination of arms 2 and 3.  All detected 
recurrences are managed by MDTs which include access to liver and 
lung resectional surgery.  The Trial is funded by the NHS R&D Health
Technology Assessment Programme.
The trial has completed its pilot phase in 6 hospital sites.  Eligibility
was lower than anticipated with only 50% of patients being eligible
rather than the 84% predicted.  This was mainly due to the discovery of 
metastatic disease when patients were fully staged. Approximately 50%
of those eligible approached consented to randomisation.  A sample of 
31 patients who completed a non participation questionnaire revealed 
that 4 declined because they did not wish arm 1 (one of these also did 
not want arm 4), 8 did not want to have hospital follow up (one of these
also did not want arm 1) and 13 (42%) were not prepared to participate
in any research study.  Experience with the pilot also revealed excessive
unnecessary delays related to LREC/R&D/Research governance and 
Primary Care requirements.  On one occasion, this resulted in a 2 year 
delay in setting up a centre.   
The FACS trial is feasible and acceptable to patients although there is
evidence of a reduced willingness of patients to participate in clinical
trials in general.  On the basis of the pilot the full study will involve 100
trial sites each aiming to recruit around 2 patients per month.  The trail
is now open to recruit additional centres.
P172
PILOT ‘PROOF OF CONCEPT’ STUDY OF ELECTRONIC
REMOTE DATA CAPTURE (ERDC) APPLIED TO AN ACADEMIC, 
MULTI-CENTRE, PHASE III ONCOLOGY CLINICAL TRIAL
MCM Jones, RM Harpin
National Cancer Research Network, Leeds, United Kingdom
It has been identiﬁ  ed that the entry of patients into clinical trials could 
be expedited through the use of eRDC technology.  A pilot study to start 
investigating this claim has been carried out to assess the viability of using 
ICT to support clinical trials and develop an iterative programme for a 
national rollout.  The purpose of the pilot was to demonstrate ‘proof of 
concept’ that eRDC could be successfully employed for the collection 
and storage of real patient information for an academic, multi-centre, 
Phase III clinical trial.  This was achieved from a user perspective by 
using eRDC to capture parallel data on an existing trial and a technical 
evaluation of a secure hosted managed service (with benchmarking o f 
software applications to ensure ‘value for money’).  The potential beneﬁ  ts 
to be gained from using such technology are improved speed, quality and 
security of clinical trial information.  This is achieved by cutting the time 
involved in CRF authoring, database development and protocol launch. 
By using data validation data discrepancies are minimised which in turn 
reduces time to data locking.  Data is available in real time for interim 
analysis and review.  There is a reduction in the need for data entry staff, 
highly qualiﬁ  ed computer programmers, research staff and storage for 
paper Case Report Forms (CRFs).  As these beneﬁ  ts are realised time can 
be spent more efﬁ  ciently on accruing patients into trials and potentially, 
more trials could be run.  The use of eRDC was tested alongside standard 
paper-based systems for the COMICE trial.  Complete consideration was 
given to security, integration with existing systems and IT capability prior 
to the application being piloted across the networks. This project had a very 
positive user experience and satisﬁ  ed the ethical and security requirements 
of the Caldicott Guardians and DPA.  A Phase 2 is planned and will be a 
multi-centre/multi-trial study to demonstrate scalability and will explore the 
full functionality of a Clinical Data Management System (CDMS).
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PATIENT ELIGIBILITY SCREENING AND NURSING 
WORKLOAD IN A TRIALS ACTIVE CANCER CENTRE
S H Shankland, L A Batt, T S Maughan, Velindre Cancer Centre,
Cardiff, UK
Background - A recent audit in Cardiff highlighted that 16% of new
breast cancer patients entered a clinical trial, but this ﬁ  gure is not
reproduced in other disease sites.  In January 2002 patient screening
forms and clinic diaries were introduced at the Velindre Hospital Cancer 
Centre to record details of all patients potentially eligible for trials and 
to estimate how long research nurses spent with patients managing the
range of clinic visits required.
Methods - Data were collected over an eight week period by research
nurses.
Screening Forms
Completed for patients in all major disease sites.
Research team screened notes before each clinic.
Highlighted potential trial patients.
Information to clinicians as a prompt to approach patients.
Clinic Diaries
Captured the clinic activity of 9 research nurses.
Categorised visits - informed consent, treatment or follow up.
Time spent per patient was recorded. 
Results - Commercial studies required approximately 4 times as long
for Informed Consent (2hrs 6mins vs 34 mins) as publicly funded 
studies.  On treatment visits for commercial studies take twice as long
(35 mins vs 17 mins). No difference was observed in the length of time
follow up visits took (18-20 mins). The trials included in the audit
ranged from very simple to much more complex.
Conclusions and Further Research
Average times have been calculated but in practice the complexity of 
each individual trial has to be considered in order to generalise these
data.
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ASSESSING CANCER TRIAL COMPLEXITY AND ITS IMPACT 
ON WORKLOAD
LA Batt, LK Branston, TS Maughan, Velindre Cancer Centre,
Cardiff, UK
Introduction - The current portfolio of oncology trials open to
recruitment in Wales includes a broad range of trial designs from
genetic and epidemiological studies to palliative trials in advanced
cancer.  When comparing recruitment rates between hospitals, WCTN
wanted to account for the levels of complexity of the trials open at each
hospital.
Trial complexity has an impact on:
Where a trial can be run - Cancer Unit versus Cancer Centre
Research staff workload
Demands on hospital departments – radiology, pharmacy, nursing
Ethical, R&D and costing requirements
Methods - We reviewed 46 trials that had recruited > 5 patients in
2002. A scoring system was devised to reﬂ  ect the procedures, tests,
data collection and design of each protocol. Protocols were used as a
reference and details checked with research staff running the trial.
20 parameters were deﬁ   ned and scored according to the workload
involved.  The maximum possible score was 37.
Results - Total complexity scores ranged from 5 - 27.  These crude
scores were banded in ranges 1 (least complex) – 5 (most complex).
Conclusions and Further Work - An assessment of trial complexity is
essential when reviewing research units’ output and comparing accrual
rates. Access to NHS facilities affects the type of trials that can be run
and the UK portfolio needs to cater for cancer centres and units. This
analysis suggests the most complex trial is approximately 5 times more
involved than the simplest study but this may be an underestimate. Our
results need review by NCRN networks. Complexity measures would
facilitate performance management and workforce planning.
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A SURVEY OF U.K CANCER CENTRES USE OF TOTAL BODY 
IRRADIATION
N van As, V Wolstenholme, G Mikhaeel
Guys and St Thomas’, London, United Kingdom
Total body irradiation (TBI) is used for a number of different
conditions. It can be associated with signiﬁ  cant morbidity. There are
no clear guidelines as to how TBI should be prescribed or delivered, nor 
how patients should be followed up. In our survey we look at practice,
technique and follow up procedure in UK cancer centres.
We contacted all the centres in the UK by telephone to ﬁ  nd out which
centres offer TBI. Of the 56 cancer centres in the UK, 31 offer TBI.  All
centres offering TBI were then sent questionnaires. The questionnaires
were divided into two sections. The ﬁ   rst section was aimed at the
consultants prescribing and responsible for TBI. The second section
was aimed at the physicists who are involved in TBI.
The questionnaires were sent in December 2003, and to date we have
received 66% of the questionnaires. We intend to follow up by telephone
calls and sending second questionnaires to improve the response rate
those who have not responded by the end of February. 
Interim analysis of the results revealed some interesting ﬁ  ndings. All
patients are assessed and consented by Clinical Oncology consultants
prior to TBI, but despite this, very few Clinical oncologists follow up
patients after TBI.
We examined a number of different issues including indications,
dose, fractionation, ﬁ  eld arrangement, patient position, use of bolus
and assessment of dosimetry. To date, the preliminary data is very
interesting and we look forward to reporting our full data.
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THE PIMS TRIAL: A RANDOMISED CONTROLLED TRIAL OF 
PELVIC IMRT FOR MULTIPLE TUMOUR SITES
J N Staffurth 1, E Hall 3, M Powell 4, V Khoo 2, D Tait 2, M Bidmead2,
D Dearnaley 2, P Wells 4, P Blake 2, M Sydenham 3, PIMS Trial
Development Group 1
1 Egypt, Velindre Hospital, Cardiff, 2 United Kingdom, Royal Marsden
NHS Trust, London, 3 United Kingdom, Institute of Cancer Research, 
London, 4 United Kingdom, Barts and the London NHS Trust, London
Introduction: The incidence of toxicity from whole pelvic radiotherapy 
(WPRT) is related to the volume of bowel irradiated to high doses. Preclinical 
studies of IMRT for WPRT have shown a reduction in the volume of bowel 
irradiated to high dose, which may lead to reduced toxicity. Initial clinical 
experience from phase 1 trials and non-randomised series has been encouraging. 
We are designing a randomised trial to investigate the ability of IMRT to reduce 
the toxicity of WPRT for prostate, gynaecological and rectal tumours.
Study design: P hase III multi-centre, non-blinded randomised trial,
stratiﬁ  cation by tumour site and centre. Planned sample size of 600 patients
randomised in a 1:1 ratio to the IMRT or conformal-RT arm.
Endpoint: Primary endpoint is late gastrointestinal radiation toxicity:
Grade 2 or greater using NCI CTC v. 3.0 Late Radiation Morbidity
Score. Secondary endpoints are late genitourinary radiation toxicity, acute
radiation toxicity, quality of life, tumour control and survival.
Entry criteria: Locally advanced  Prostate  adenocarcinoma  with
≥30% estimated r isk o f  pelvic nodal  involvement.  Cervical  carcinoma
with  high r isk o f pelvic  failure after TAH (+/-lymphadenectomy).
Endometrial adenocarcinoma with high risk of pelvic failure after TAH
(+/-lymphadenectomy).  Rectal  adenocarcinoma suitable for long-course
pre-operative (chemo-) radiation.
Treatment protocol: Target volumes and organs at risk to be outlined on
every CT slice in both arms; patients in the control arm will be treated with
conformal radiotherapy. The same biologically effective doses will be used
in both arms of the study. Standard neoadjuvant, concurrent and adjuvant
therapies will be the same for each arm (deﬁ  ned by tumour subgroup).
Quality Assurance: An emphasis will  be made to develop a quality
assurance program to ensure accuracy of outlining, planning and delivery
throughout the trial.
Posters
S79
British Journal of Cancer (2004) 91(Suppl1), S24–S80 & 2004 Cancer Research UKP176:1
THE MARS (MESOTHELIOMA AND RADICAL SURGERY)
TRIAL
MA Sydenham 1, C Peckitt 1, S Piggott 1, J Peto 1, D Waller 3,
T Treasure 2, MARS Trial Management Group 1
1 United Kingdom, Institute of Cancer Research, Sutton, 2 United 
Kingdom, Guys and St Thomas’ Hospital, London, 3 United Kingdom, 
Glenﬁ  eld Hospital, Leicester
Introduction: The role of radical surgery in mesothelioma has never 
been tested in a randomised trial.  Cancer Research UK has given
funding for a 50 patient pilot study.
Pilot Study: The pilot study will  determine the  feasibility and 
acceptability of performing a randomised trial comparing extra-pleural
pneumonectomy (EPP) against no EPP surgery within the context
of trimodality therapy  (chemotherapy, surgery and post-operative
radiotherapy).
Methodology for Pilot Study: Agreement of the study design has
been difﬁ  cult and contentious.  Consensus has been reached and the
protocol submitted  for MREC approval.  Patients with potentially
operable disease on staging will ﬁ  rst be registered at the local centre,
where they will have 3 cycles of cisplatin based chemotherapy.  The
patients will then be restaged following the chemotherapy.  The local
centre, surgical centre and MARS Multi Disciplinary Teams will assess
the ﬁ  nal eligibility.  Patients eligible for surgery will be randomised to
EPP or no EPP surgery.  Patients randomised to receive EPP will be
referred to a designated surgical centre.  After surgery patients will be
given radical hemithoracic radiotherapy.  Patients randomised to no EPP
surgery will receive active oncological management at the local centre.
Quality of life will be measured at various time points throughout the
trial.
Main Trial: If the pilot study is successful it will lead to a main trial, the
aim of which is to determine if surgery is beneﬁ  cial, in terms of survival
& quality of life.  The target is to recruit 700 patients over 3 years into
a Europe-wide trial.
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PROSPECTIVE RANDOMISED TRIAL TESTING 5.7GY AND 6.0GY
FRACTIONS OF WHOLE BREAST RADIOTHERAPY IN WOMEN WITH
EARLY BREAST CANCER (‘FAST’ TRIAL)
D Bloomﬁ  eld 4, M Sydenham 1, J LeVay 3, I Syndikus 5, M Hatton 6, P Bliss 7, P Dyson 
8, S Kelly 9, R Agrawal 10, P Barrett-Lee 11, C Abson 12, JR Owen 13, S Kumar 14,
M Brunt 15, L Whipp 16, M Illsley 17, J Bliss 1, J Yarnold 2
1 United Kingdom, Institute of Cancer Research, Sutton, 2 United Kingdom, Royal Marsden 
Hospital, Sutton, 3 United Kingdom, Ipswich Hospital, Ipswich, 4 United Kingdom, Royal
Sussex County Hospital, Brighton, 5 United Kingdom, Clatterbridge Centre for Oncology, 
Bebbington, 6 United Kingdom, Weston Park Hospital, Shefﬁ  eld, 7 United Kingdom, 
Torbay Hospital, Torbay, 8 United Kingdom, Cumberland Inﬁ  rmary, Carlisle, 9 United 
Kingdom, Derriford Hospital, Plymouth, 10 United Kingdom, Royal Shrewsbury Hospital,
Shrewsbury, 11 United Kingdom, Velindre Hospital, Cardiff, 12 United Kingdom, Kent 
Oncology Centre, Maidstone, 13 United Kingdom, Gloucestershire Oncology Centre,
Cheltenham, 14 United Kingdom, Cookridge Hospital, Leeds, 15 United Kingdom, Stafford 
General Hospital, Stoke on Trent, 16 United Kingdom, Bristol Haematology and Oncology 
Centre, Bristol, 17 United Kingdom, Royal Surrey County Hospital, Guildford
Background: There is a resurgence of interest in the potential biological and clinical
beneﬁ  ts of fewer, larger radiotherapy fractions for breast radiotherapy.
Aim: To test 5 fractions of 5.7Gy and 6.0Gy against 25 fractions of 2.0Gy in terms
of late normal tissue effects and tumour control in women prescribed whole breast
radiotherapy  (no  boost) a fter  local excision of early  breast cancer in a prospective
randomised controlled clinical trial.
Inclusion criteria: Age ≥50 years, invasive carcinoma breast, breast conservation surgery,
pathological tumour size <3.0 cm, complete microscopic resection, axillary node negative
Exclusion criteria: Mastectomy,  lymphatic radiotherapy, radiotherapy  breast  boost,
neoadjuvant or adjuvant cytotoxic therapy.
Randomisation:
Control arm: 50.0Gy in 25 fractions of 2.0Gy in 35 days
Test arm 1: 30.0Gy in   5 fractions of 6.0Gy in 35 days
Test arm 2: 28.5Gy in   5 fractions of 5.7Gy in 35 days
Test arm 3: 30.0Gy in   5 fractions of 6.0Gy in 15 days
Test arm 4: 28.5Gy in   5 fractions of 5.7Gy in 15 days
Radiotherapy delivery: Tangential ﬁ  elds to the whole breast; no boost; with full dose
compensation
Primary endpoint: Change in photographic breast appearance.
Secondary endpoint: Tumour recurrence in the breast.
Sample size: 1500
Discussion: The aim is to complete accrual into this pilot study by September 2005
(before the IMPORT trial starts). A proposal based on 2-year outcome data will be
submitted in 2006 for a phase 3 trial using tumour control as the primary endpoint.
The goal is to evaluate a 5-fraction schedule of intensity modulated radiotherapy as the
standard of care for this large population of patients by 2010.
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RANDOMISED TRIAL TESTING INTENSITY MODULATED 
RADIOTHERAPY AND PARTIAL PARTIAL  P ORGAN RADIO RADIO R THERAPY IN EARLY
BREAST CANCER (IMPORT TRIAL)
C Coles 3, E Donovan 2, K Venables 4, C Rawlings 5, H Mayles 6, S Bentzen 7,
M Sydenham 1, J Bliss 1, J Yarnold 2, IMPORT Working Party 1
1 United Kingdom, Institute of Cancer Research, Sutton, 2 United Kingdom, 
Royal Marsden Hospital, Sutton, 3 United Kingdom, Addenbrookes Hospital, 
Cambridge, 4 United Kingdom, Mount Vernon Hospital, Northwood, 5 United 
Kingdom, Torbay Hospital, Torbay, 6 United Kingdom, Clatterbridge Centre for 
Oncology, Bebbington, 7 United Kingdom, Gray Cancer Institute, Northwood
Background: Standard radiotherapy aims to distribute dose evenly across the
breast, even though local tumour recurrence is concentrated in the index quadrant.
Dose intensiﬁ  cation is achieved by giving additional fractions (sequential boost).
Dose intensity modulation adjusted to individual recurrence risk and to the pattern
of relapse in the breast would be much more effectively achieved by dose intensity
modulation across the breast and fewer fractions.
Aim: To test dose  intensity modulation and partial  breast radiotherapy a fter 
conservation surgery for early stage breast cancer.
Eligibility: Age 18 years and above, operable unilateral breast cancer (T1-3,
N0-1, M0) at presentation, breast conserving surgery, histological conﬁ  rmation
of invasive carcinoma, complete microscopic resection, written informed consent
and availability for follow-up.
Study design: The control arm delivers 40Gy/15 fractions (F) to whole breast
volume; Sequential boost 16Gy/8F to tumour bed, if indicated. The test arm
delivers: 36Gy/15F to low dose breast volume (outside index quadrant); 40Gy/
15F to standard dose breast volume (includes index quadrant); Concomitant boost
48Gy/15F or 53Gy/15F to tumour bed, if indicated.
Primary endpoint: Local tumour control. Secondary endpoints include location
of tumour relapse in breast, metastases, late adverse effects in normal tissues,
quality of life and economic evaluation.
Sample size: 4000 patients will provide 90% power to detect a difference of 3% in
5-year recurrence rates (assuming a 10% recurrence rate at 5 years in the control
arm, 5% rate of loss by 5 years follow-up).
Discussion: Modulation of fraction size promises to be superior to adjustment of 
fraction number for risk-adapted radiotherapy. The results of the proposed IMPORT 
trial combined with the results of the START and FAST trials are expected to underpin 
future 3D intensity modulated breast radiotherapy delivered in 5 fractions over 5 – 15 
days as the standard of care for up to 20,0000 women per year in the UK.
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THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS
OF TREATMENT FOR CLINICALLY LOCALISED PROSTATE 
CANCER (ISRCTN20141297)
JA Lane 1, FC Hamdy 2, DE Neal 3, JL Donovan 1, The ProtecT study group 1
1 United Kingdom, University of Bristol, Bristol, 2 United Kingdom, 
University of Shefﬁ  eld, Shefﬁ  eld, 3 United Kingdom, University of 
Cambridge, Cambridge
Aims and Methods: The ProtecT study is a UK multi-centre randomised
controlled trial o f t he effectiveness, cost-effectiveness and acceptability
of treatments for clinically  localised prostate cancer preceded  by case
ﬁ  nding  in  general practices. The trial compares three treatments: active
monitoring by PSA (prostate speciﬁ  c antigen), radical prostatectomy and
radical radiotherapy. Qualitative research is used extensively to investigate
methods of giving information to participants as well as in-depth case studies
of participants’ experiences3. The primary outcome is survival at 10 years
with secondary outcomes of disease progression, treatment complications,
urinary symptoms, sexual function, QoL and health service utilisation.
Results:   The study commenced in 1999 and will recruit over 100,000
unselected men. There are nine centres recruiting across the UK. Currently,
over 33,000 men have been recruited (50% of those invited) and 2,884 have
a raised PSA test (10.0%). There are 823 men with prostate cancer (25%
of those with a raised PSA) of which 622 have clinically localised disease
and 460 men have been randomised
Extensive qualitative research has increased randomisation rates from less
than 50% at the start of the study to over 70% currently. Analyses of the
qualitative data has helped improve information given to participants as
well as patient information sheets.
Conclusions: This large randomised trial focuses on an area of clinical
uncertainty around the most appropriate treatment for localised prostate
cancer. Major insights into the conduct of randomised trials have been
gained through the novel use of qualitative research methods. The results
of this trial will inform UK policy for prostate cancer treatment. 
References
1. Majeed A, Babb P, Jones J, Quinn M. BJU Int 2000; 85:1058. t
2. Selley S, Donovan JL,et al. HTA. Programme: HTA, 1997; 1 (2).
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